Is placenta previa a determinant of preeclampsia?

Jelsema, Russel D.; Bhatia, Rupinder K.; Zador, Ivan E.; Bottoms, Sidney F.; Sokol, Robert J.

doi:10.1515/jpme.1991.19.6.485

Cited by 9 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the present data provides indirect evidence that the oxygen demands of the placenta and developing fetus of women with placenta previa are most frequently reached when trophoblast penetration of the lower uterine segment myometrium is appropriate. The observation that women with placenta previa and physiologic myometrial invasion have a normal serological profile of VEGF, PlGF and sFlt-1, is consistent with none of the fetuses in our cohort being growth restricted and with the literature refuting placenta previa as an independent risk factor for IUGR or preeclampsia 33,34…”

Section: Commentsupporting

confidence: 91%

Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast

Wehrum

Buhimschi

Salafia³

et al. 2011

American Journal of Obstetrics and Gynecology

105

View full text Add to dashboard Cite

OBJECTIVE-To characterize serum angiogenic factor profile of women with complete placenta previa and determine if invasive trophoblast differentiation characteristic of accreta, increta or percreta shares features of epitehelial-mesenchymal-transition (EMT).STUDY DESIGN-We analyzed gestational age matched serum samples from 90 pregnant women with either complete placenta previa (n=45) or uncomplicated pregnancies (n=45). Vascular-endothelial-growth-factor (VEGF), placental-growth-factor (PlGF) and soluble fms-liketyrosine-kinase-1 (sFlt-1) were immunoassayed. VEGF and phosphotyrosine (P-Tyr) immunoreactivity was surveyed in histological specimens relative to expression of vimentin and cytokeratin-7. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. RESULTS-Women Disclosure statement:The authors have nothing to disclose CONTRIBUTIONS TO AUTHORSHIP MJW, EF, IAB and CSB formulated the hypothesis, designed the study, collected, analyzed, and interpreted the data and drafted the manuscript. MJW and CSB recruited patients and together with ST, MOB, EW, KC, AKS and CL collected biological specimens and followed the patients prospectively to the point of delivery. MJW and GZ conducted the ELISA assays and the immunohistochemistry experiments. IAB, MJW, CSB and CMS evaluated and performed the histological analysis of our specimens. All the co-authors participated with aspects of study design, critical interpretation of the data, contributed to writing of the paper and have reviewed and approved the final version. NIH Public Access Author ManuscriptAm J Obstet Gynecol. Author manuscript; available in PMC 2012 May 1. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript CONCLUSIONS-Lower systemic free VEGF and a switch of the interstitial EVT to a metastable cell phenotype characterize placenta previa with excessive myometrial invasion.

show abstract

Section: Commentsupporting

confidence: 91%

Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast

Wehrum

Buhimschi

Salafia³

et al. 2011

American Journal of Obstetrics and Gynecology

105

View full text Add to dashboard Cite

show abstract

“…Some other studies had reported a 50% reduction in pre-eclampsia in these women (12). Jelsema did not find any relationship between placenta previa and the incidence of pre-eclampsia (13). In all mentioned studies, the sample size was small, and therefore designing a meta-analysis study can offer reliable results about the association between placenta previa and pre-eclampsia.…”

Section: Introductionmentioning

confidence: 91%

“…Three studies were case-control (8,17,18), five studies were cohort (13,(19)(20)(21)(22), and one study was cross-sectional (23). The total sample size in the present meta-analysis was 752,243 participants.…”

Section: Description Of Studiesmentioning

confidence: 99%

The association between placenta previa and the risk of preeclampsia: a meta-analysis

Khazaei¹

2019

Erciyes Med J

View full text Add to dashboard Cite

There are contradicting results regarding the effect of previa on pre-eclampsia. Therefore, the aim of the present study was to systematically review the relevant literatures and to determine the association between placenta previa and pre-eclampsia in pregnant women. Electronic scientific databases including Scopus, PubMed, and Web of Science were searched to identify relevant published studies. Two independent authors studied the selected studies and extracted data. I 2 statistics was used to assess the variation across studies. The random effects model was used to assess pooled effect sizes. Data were analyzed through Stata software version 12. The results of the present meta-analysis of nine studies indicated a significant relationship between placenta previa and risk of pre-eclampsia. The odds of pre-eclampsia were 0.55 (95% confidence interval (CI) 0.26-0.85) in placenta previa cases compared with the control groups and 0.17 (95% CI 0.07-0.27) in studies with adjustment on confounder variables. Our results showed that placenta previa is associated with a decrease incidence of pre-eclampsia.

show abstract

“…There have been inconsistent findings with respect to the relationship between PE and PP: Ananth et al[ 8 ] reported in 1997 that the presence of PP could reduce the incidence of PE by 50%. However, Hasegawa and Adam[ 4 , 5 ], found no cases of PE present in women with PP, and Jelsema [ 9 ]reported that the presence of PP did not lower the incidence of PE. However, the sample sizes of these studies were small, with numbers of PP cases ranging from 200 to 300 [ 4 , 5 , 8 , 10 ], and most of these studies did not take into consideration the influence of interfering factors such as BMI on the results of the study [ 8 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Placenta Previa on Preeclampsia

et al. 2016

View full text Add to dashboard Cite

BackgroundThe correlation between gestational hypertension-preeclampsia (GH-PE) and placenta previa (PP) is controversial. Specifically, it is unknown whether placenta previa has any effect on the various types of preeclampsia (PE), and the role PP with concurrent placenta accreta (PA) play in the occurrence of GH-PE are not well understood.ObjectiveThe aim of this study was to identify the effects of PP on GH, mild and severe preeclampsia (MPE and SPE), and early- and late-onset preeclampsia (EPE and LPE). Another aim of the study was to determine if concurrent PA impacts the relationship between PP and GH-PE.MethodsA retrospective single-center study of 1,058 patients having singleton pregnancies with PP was performed, and 2,116 pregnant women were randomly included as controls. These cases were collected from a tertiary hospital and met the inclusion criteria for the study. Clinical information, including PP and the gestational age at the onset of GH-PE were collected. Binary and multiple logistic regression analyses were conducted after the confounding variables were controlled to assess the effects of PP on different types of GH-PE.ResultsThere were 155 patients with GH-PE in the two groups. The incidences of GH-PE in the PP group and the control group were 2.5% (26/1058) and 6.1% (129/2116), respectively (P = 0.000). Binary and multiple regression analyses were conducted after controlling for confounding variables. Compared to the control group, in the PP group, the risk of GH-PE was reduced significantly by 78% (AOR: 0.216; 95% CI: 0.135–0.345); the risks of GH and PE were reduced by 55% (AOR: 0.451; 95% CI: 0.233–0.873) and 86% (AOR: 0.141; 95% CI: 0.073–0.271), respectively; the risks of MPE and SPE were reduced by 73% (AOR: 0.269; 95% CI: 0.087–0828) and 88% (AOR: 0.123; 95% CI: 0.055–0.279), respectively; and the risks of EPE and LPE were reduced by 95% (AOR: 0.047; 95% CI: 0.012–0.190) and 67% (AOR: 0.330; 95% CI: 0.153–0.715), respectively. The incidence of concurrent PA in women with PP was 5.86%; PP with PA did not significantly further reduce the incidence of GH-PE compared with PP without PA (1.64% vs. 2.51%, P>0.05). Binary logistic regression analyses were conducted after controlling for confounding variables, compared with the non-PP + GH-PE group, and the AOR of FGR in the non-PP + non-GH-PE group was 0.206 (0.124–0.342). Compared with the PP + GH-PE group, the AOR of FGR in the PP + non-GH-PE group was 0.430 (0.123–1.500).ConclusionPP is not only associated with a significant reduction in the incidence of GH-PE, but also is associated with a reduction in incidence of various types of PE. Concurrent PA and PP do not show association with a reduction in incidence of GH-PE.

show abstract

Is placenta previa a determinant of preeclampsia?

Cited by 9 publications

References 8 publications

Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast

Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast

The association between placenta previa and the risk of preeclampsia: a meta-analysis

Effect of Placenta Previa on Preeclampsia

Contact Info

Product

Resources

About